Enovis Corp (ENOV) Stock Analysis
Verdict: HOLD
Massive valuation gap between current P/S (0.53x) and forward earnings potential ($3.65 EPS in 2026) hinges on debt-fueled reconstruction growth.
Investment score: 64/100
Analysis as of
Is Enovis Corp stock worth reviewing? The TradeMates thesis
ENOV is a distressed-priced med-tech play with 60% gross margins and a path to $3.65 EPS by 2026, currently trading at a fraction of peer multiples.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Enovis Corp opportunities and risks
What speaks for ENOV
- Deep Valuation Discount
What speaks against ENOV
- High Leverage and Balance Sheet Strain
Peers and competitors
- IART
- ATEC
- AVR.AX
- ASST
- PRCT
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ENOV | n/a | 0.5x | n/a | 56.8% | -49.9% | 3.0% |
| IART | n/a | 0.8x | n/a | 53.2% | -30.1% | -0.7% |
| ATEC | n/a | 1.6x | n/a | 65.3% | -15.9% | 0.5% |
| ASST | n/a | 202.7x | n/a | -353.8% | -11945.2% | -3.4% |
| PRCT | n/a | 3.7x | n/a | 63.0% | -31.8% | -6.7% |
| Peer median | n/a | 2.7x | n/a | 58.1% | -31.0% | -2.1% |
Frequently asked questions about Enovis Corp (ENOV)
Is ENOV stock a good investment?
The TradeMates model rates Enovis Corp as HOLD with an investment score of 64/100. ENOV is a distressed-priced med-tech play with 60% gross margins and a path to $3.65 EPS by 2026, currently trading at a fraction of peer multiples. This is algorithmic model output, not personal investment advice.
Is ENOV stock a buy?
The TradeMates model verdict for ENOV is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.